Clinical Trials
- A Clinical Investigation To Evaluate The Safety And Performance Of The Freedom Total Knee® System With The PEEK-OPTIMA Femoral Component
- Effect of Patient Education in Rheumatic Diseases
- LPS Flex Porous Femoral Components
- NexGen TM Tibia Clinical Outcomes Study
- Persona 0° Keel Randomized Controlled Trial
- Persona OsseoTi Keel Compatibility Study (TKA)
- Persona Ti-Nidium Post-Market Clinical Follow-up
- Persona TM Tibia Clinical Outcomes Study
- Persona Total Knee Arthroplasty Outcomes Study
- Study of the Impact of Fatty Acids From Seal Oil on the Relief of Symptoms Associated With Rheumatoid Arthritis
- Synovial Fluid Bank From Arthritic Patients
- The Medacta International GMK Sphere Cementless Post-Marketing Surveillance Study
- The Medacta International GMK Sphere Post-Marketing Surveillance Study
- The Use of Anti-CD4 Monoclonal Antibody (mAb)-Fragment for the Imaging of Chronic Inflammation in Patients With Active Rheumatoid Arthritis
- Zimmer POLAR – Total Knee Arthroplasty (TKA)
- Zimmer POLAR Persona – TKA (EMEA Study)
- 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
- A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
- A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
- A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)
- A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases – PHOENIX
- A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
- A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
- A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
- A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
- A Trial of Bardoxolone Methyl in Patients With ADPKD – FALCON
- ADPKD Alterations in Hepatic Transporter Function
- ADPKD and Peritoneal Dialysis: How Anticipate Peritoneal Pressure?
- ADPKD Cohort Study
- ADPKD Patient Registry
- Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease
- An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
- Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease)
- Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD
- Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository
- Canadian Medical Assessment of JINARC™ Outcomes Registry
- Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD
- Clinical Implications of DNA Analysis on ADPKD
- Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease
- Daily Caloric Restriction in ADPKD
- Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease
- Dietary Intervention in ADPKD on Tolvaptan
- Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
- Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal Function
- Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease
- Effect of the Aquaretic Tolvaptan on Nitric Oxide System
- Effects of Somatostatin on ADPKD Heart
- Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
- Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
- Efficacy of Tolvaptan on ADPKD Patients
- Efficacy Study of Water Drinking on PKD Progression.
- Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
- Establishment of the Human Intestinal and Salivary Microbiota Biobank – Kidney Diseases
- Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
- Evaluation of Iliac and Renal Artery for Mechanism of Intracranial Aneurysm in ADPKD
- Evaluation of Nephrectomy Specimen for Intracranial Aneurysm Development in ADPKD
- High Water Intake in Polycystic Kidney Disease
- IMPEDE-PKD Randomised Placebo-controlled Trial
- Intrarenal Microvasculature in ADPKD
- Lanreotide In Polycystic Kidney Disease Study
- Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
- Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease
- New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease
- NOX4 and Related Biomarkers in ADPKD
- Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
- Open-Label Tolvaptan Study in Subjects With ADPKD
- Open-label, Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303
- Outcome of Autosomal Dominant Polycystic Kidney Disease Patients on Peritoneal Dialysis: a National Retrospective Study Based on Two French Registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network).
- PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
- Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- PKD Biomarkers Study
- PKD Clinical and Translational Core Study
- Polycystic Kidney Disease Data Repository
- Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
- Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
- Renal Sympathetic Denervation for Reduction of Pain and Improvement of Insulin Sensitivity in Adult Polycystic Kidney Disease
- Repository Study of Autosomal Dominant Polycystic Kidney Disease
- Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
- Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)
- Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Sirolimus for Massive Polycystic Liver
- Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
- Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency
- Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study
- Statin Therapy in Patients With Early Stage ADPKD
- Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
- Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
- The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
- The ELiSA Study – Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
- The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe
- The German ADPKD Tolvaptan Treatment Registry
- The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain
- Thyroid Hormones in ADPKD
- To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects
- Tolvaptan-Octreotide LAR Combination in ADPKD
- Treatment of Vascular Stiffness in ADPKD
- Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
- Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
- A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
- A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
- Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts
- Automatic Segmentation of Polycystic Liver
- Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
- Everolimus and LongActing Octreotide Trial in Polycystic Livers
- Lanreotide as Treatment of Polycystic Livers
- Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
- Octreotide in Severe Polycystic Liver Disease
- Open-Label Extension of LOCKCYST Trial
- Pasireotide LAR in Severe Polycystic Liver Disease
- Polycystic Liver Disease in Kidney Transplant
- Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
- The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
- Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
- 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- A Phase 1 Study of XL019 in Adults With Polycythemia Vera
- A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
- A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis
- A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
- A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
- A Safety Study of XL019 in Adults With Myelofibrosis
- A Study in Myeloproliferative Disorders
- A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
- A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
- A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
- A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
- A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
- An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
- Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
- Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
- Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
- Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders
- Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice
- Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
- Correlative Biomarker Study in Patients With Myeloproliferative Disorders
- CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia
- Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
- Dasatinib in Polycythemia Vera
- Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
- Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients
- Dual Vaccine Trial in Myeloproliferative Neoplasms
- Effect of Phlebotomy on Heartrate in Polycythemia Patients
- Effects of Imatinib Mesylate in Polycythemia Vera
- Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
- Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera
- Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms
- Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
- Extension Study After Completion of Phase 2 Study for P1101 With Polycythemia Vera (PV) Patients (Study A19-201)
- Familial Myeloproliferative Disorders
- Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
- Hepcidin Mimetic in Patients With Polycythemia Vera
- IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
- Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features
- Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)
- MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
- Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders
- Myeloproliferative Neoplasms and Bone Structure
- Myeloproliferative Neoplasms: an In-depth Case-control Study
- Myeloproliferative Neoplastic Diseases Observatory From Brest
- Natural Killer Cells and Polycythemia Vera (Vaquez’s Disease)
- Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
- Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
- PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
- Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
- Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
- Pomalidomide for Myelofibrosis Patients
- PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit
- Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
- Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
- Research Tissue Bank
- Ruxolitinib and Daunorubicin (CPX-351) in Treating Patients With Secondary Acute Myeloid Leukemia Transformed From Myeloproliferative Neoplasms
- Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
- Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.
- Ruxolitinib in Thrombocythemia and Polycythemia Vera
- Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
- Safety Evaluation Study for Patients With Polycythemia Vera
- Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
- Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera
- Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
- Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
- Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
- Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
- Study to Assess SLN124 in Patients With Polycythemia Vera
- Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
- Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients
- Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera
- Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation
- TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
- The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
- Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
- Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
- Tissue Banking Study – Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
- To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy.
- Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
- Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
- Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
- A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
- A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
- Abatacept Treatment in Polymyositis and Dermatomyositis
- Adult and Juvenile Myositis
- Anakinra in Myositis
- Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM
- Dermatomyositis and Polymyositis Registry
- Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies
- Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis
- Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)
- Efficacy and Tolerability of BAF312 in Patients With Polymyositis
- Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
- Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis
- Environmental Risk Factors for Myositis in Military Personnel
- Environmental Risk Factors for the Anti-synthetase Syndrome
- Epidemiological Study of Inflammatory Myopathies in a French Region
- Evaluate the Safety, Tolerability and Efficacy of PN-101 in Patients With Refractory Polymyositis or Dermatomyositis
- Hand Function in Patients With Poly- or Dermatomyositis
- High-intensity Strength Training in Myositis
- Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis
- Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
- Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus
- Methimazole to Treat Polymyositis and Dermatomyositis
- Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties
- myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies
- Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
- Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
- Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)
- Plexin D1 as a Potential Biomarker inPM/DM
- Predictor of Clinical Response to Acthar in Myositis
- Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
- Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
- Study and Treatment of Inflammatory Muscle Diseases
- Study of M5049 in DM and PM Participants (NEPTUNIA)
- Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy
- Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
- Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
- Ultrasound Evaluation of Tongue Movements in Speech and Swallowing
- A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
- A Long Term Follow up Study in Late-onset Pompe Disease
- A Long-term Study for the Outcome of Pompe Disease
- A Natural History Study of Adult Onset Pompe Disease Using Muscle MRI
- A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease
- A Pilot Study of Pyridostigmine in Pompe Disease
- A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction
- A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease
- A Prospective, Observational Study in Patients With Late-Onset Pompe Disease
- A Study of rhGAA in Patients With Late-Onset Pompe Disease
- A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease
- A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II
- A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting
- A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease
- A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
- AAV2/8-LSPhGAA in Late-Onset Pompe Disease
- Albuterol in Individuals With Late Onset Pompe Disease (LOPD)
- Alglucosidase Alfa Pompe Safety Sub-Registry
- Alglucosidase Alfa Temporary Access Program
- An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
- An MRI Study on Muscular Diseases -Pompe Disease and Dystrophia Myotonica-
- Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)
- Avalglucosidase Alfa Pregnancy Study
- Carbon-13 Magnetic Resonance Spectroscopy in Glycogen Storage Diseases
- Clinical Specimen Collection From Pompe Disease Patients
- Clinical Study for IOPD Participants Less Than or Equal to 6 Months of Age to Evaluate Efficacy and Safety of Enzyme Replacement Therapy (ERT) With Avalglucosidase Alfa
- Cognitive and Neurological Pathologies in Pompe Disease
- CPAP for Infantile Pompe Disease
- Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia
- Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- Developing a Management Approach for Patients With “Late-Onset” Pompe Disease
- Development of an Assessment Tool for Health-related Quality of Life in Children and Adolescents With Pompe Disease
- Diet and Exercise in Pompe Disease
- Drug-drug Interaction Study
- Dynamic Respiratory Muscle Function in Late-Onset Pompe Disease
- Effect of Motor Development, Motor Function and Electrophysiologic Findings of IOPD Under ERT
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
- ERT in Pompe Disease: Elucidation of Molecular Structures Contributing to Enzyme Uptake and Immunoreactivity
- Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment
- Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease
- Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease
- Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease
- Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease
- Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa
- Extension Study for Patients Who Have Participated in a BMN 701 Study
- Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.
- Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies
- Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602
- Feasability and Interest of Screening for Infantile Pompe’s Diseases at Birth
- First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
- Frequency of Pompe Disease in Patients With Myalgia With or Without Hyper Ckemia – Data From the Reference Center (CERCA)
- Frequency of Pompe’s Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness
- Genetic and Family Studies of Inherited Muscle Diseases
- Growth and Development Study of Alglucosidase Alfa.
- High Dose or High Dose Frequency Study of Alglucosidase Alfa
- High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease
- High Risk Screen of Childhood Late-onset Pompe Disease in Pediatric Outpatient Clinics
- Higher Dose of Alglucosidase Alpha for Pompe Disease
- Immune Modulation Therapy for Pompe Disease
- Immune Tolerance Induction Study
- Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices
- Late-Onset Treatment Study Extension Protocol
- Lingual Muscle Training in Late-Onset Pompe Disease (LOPD)
- Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (ATBIG-Pompe-Study)
- MSOT in Pompe Disease
- Muscle Response to Enzyme Replacement Therapy in Pompe Disease
- Natural History of Pompe Disease
- Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease
- Newborn Screening Assay of Pompe’s Disease
- Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies
- Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
- Pompe Disease QMUS and EIM
- Pompe Disease Registry
- Pompe Lactation Sub-Registry
- Pompe Pregnancy Sub-Registry
- Pompe Prevalence Study in Patients With Muscle Weakness Without Diagnosis
- Pompe Telemedicine Developmental Study
- Pregnancy and Birth Outcome in Women With Pompe Disease
- Prevalence of Heterozygote Mothers for Pompe’s Disease Among Mothers Having Delivered in French Guiana
- Prevalence of Pompe’s Disease in Respiratory Clinics
- Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease
- Respiratory Muscle Training in L-Onset Pompe Disease (LOPD)
- Response to Diaphragmatic Pacing in Subjects With Pompe Disease
- rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)
- Rosella: A Study to Evaluate the Safety, PK, Efficacy, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to
- Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease.
- Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support
- Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.
- Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease
- Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy
- Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease
- Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease
- Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease
- Screening for Early Detection and Prevention of Pompe Disease in Israel Using Tandem Mass Spectrometry
- Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease
- Search for Serum/Plasma Biomarkers in Pompe’s Disease
- Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme®
- Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen
- Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease
- The Effects of Respiratory Muscle Strength Training (RMST) on Inspiratory and Expiratory Muscle Strength in Adults and Children With Pompe Disease
- VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease
- Harvoni Treatment Porphyria Cutanea Tarda
- Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda
- Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
- Risk Factors of Porphyria Cutanea Tarda (PCT)
- Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda
- Study of the Pathogenesis of Porphyria Cutanea Tarda
- 3D CT Guidance for Transjugular Intrahepatic Portosystemic Shunt Creation
- 3D Sonographic Measurement of Volumetric Flow in Transjugular Intrahepatic Porto-Systemic Shunts
- 3D-MRE for Assessing Cirrhosis and Portal Hypertension
- 8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding
- 8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding in Patients With Child A Cirrhosis
- A Combined Model Based on Spleen Stiffness, Liver Stiffness and Platelets for Assessing Portal Hypertension in Compensated Cirrhosis.
- A Novel Approach for Transjugular Intrahepatic Portocaval Shunt Creation Using Real-time Three Dimensional Roadmap
- A Novel Imging Based Quantitative Model-aided Detection of Portal Hypertension in Patients With Cirrhosis
- A Novel Spleen-dedicated Stiffness Measured by FibroScan to Evaluate Cirrhotic Portal Hypertension (CHESS2105)
- A Physical Activity Program in End-state Liver Disease
- A Pilot Study: Defining Peripheral Endothelial Function in Portal Hypertensive Cirrhotic Patients
- A Prospective Evaluation of Computerized Tomographic(CT) Scanning as a Screening Modality for Esophageal Varices
- A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
- A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
- A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension
- A Trial of Somatostatin With Endoscopic Variceal Ligation (EVL) in Control of Acute Variceal Bleeding
- ABMSC Infusion Through Hepatic Artery in Portal Hypertension Surgery for the Treatment of Liver Cirrhosis
- Acute Hemodynamic Response to Carvedilol in Children With Clinically Significant Portal Hypertension.
- An AI Model Based on Smartphone-derived Multimodality Images to Evaluate Portal Hypertension in Patients With Cirrhosis (CHESS2203)
- Anticoagulation Therapy After Splenectomy in Cirrhosis Patient
- Assessing Outcome After H-graft Shunt Placement
- Assessment of Portal Hypertension With Multiparametric MRI
- Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial
- Austrian Registry on Transjugular Intrahepatic Portosystemic Shunts
- Can MRI Evaluate Beta-blocker Response in Portal Hypertension?
- Carvedilol for Prevention of Esophageal Varices Progression
- Carvedilol vs. Propranolol in Second Prophylaxis of Variceal Bleeding
- Characterization and Pathogenesis of ACLF
- Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14
- Comparing Two Methods to Stop Vomiting of Blood Using the Endoscope
- Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis
- Correlation of Platelets Count With Endoscopic Findings in a Cohort of Egyptian Patients With Liver Cirrhosis
- CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)
- Danish Carvedilol Study in Portal Hypertension
- Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension
- DS-MCE vs EGD for Diagnosing Gastroesophageal Varices
- Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
- Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS
- Early TIPS for Ascites Study
- Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices
- Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis
- Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis
- Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis
- Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis
- Effects of a Novel Physical Exercise Program in Patients With Cirrhosis (the LFN-exercise Protocol)
- Effects of Dark vs. White Chocolate on the Postprandial Increase in Portal Pressure in Cirrhosis
- Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
- Efficacy and Safety of EUS-guided Coil Combined With Endoscopic Cyanoacrylate Injection Versus BRTO in Patients With Spontaneous Portosystemic Shunt
- Efficacy and Safety of Simvastatin in the Treatment of Portal Hypertension
- Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis
- EGD vs EUS in Diagnosing Portal Hypertension in Cirrhotic Patients.
- Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
- Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
- Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension
- Endoscopic Ruler for the Assessment of Variceal Bleeding Risks (CHESS2005)
- Endoscopic Variceal Ligation (EVL)+ Drugs Versus Endoscopic Variceal Ligation (EVL) Alone For Secondary Prophylaxis
- Esophageal Capsule Endoscopy in Children
- EUS Guided Portal-systemic Pressure Gradient Measurement
- EUS vs TJ for Liver Biopsy and Portal Pressure Gradient Measurement
- EUS-PPG vs HVPG in Portal Hypertension
- Evaluation of 3D Overlay During Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure
- Evaluation of EUS in Preventing Rebleeding After Endoscopic Cyanoacrylate Injection for Gastric Varices
- Evaluation of Long Haul COVID-19 and Vaccine Immunogenicity in Patients With Liver Disease
- Evaluation of Minimal Hepatic Encephalopathy in Patients With Cirrhosis and Portal Hypertension
- Evaluation of Probiotics in the Treatment of Portal Hypertension
- Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin
- Extension Study of Carvedilol RCT Study
- Feasibility And Safety Of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation Using A Radiofrequency Guidewire
- FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
- Hemodynamic Alterations in Liver Cirrhosis Validated by Non-invasive MR Compared to Invasive Assessment
- Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension
- Hepatectomy for Early-stage HCC Patients With CSPH
- Hepatic Venous Pressure Gradient and Elastography in Porto-sinusoidal Vascular Disorder
- HVPG for Rebleeding Risk Stratification
- HVPG-guided Laparoscopic Versus Endoscopic Therapy for Variceal Rebleeding in Portal Hypertension: A Multicenter Randomized Controlled Trial (CHESS1803)
- Impact of Fentanyl Analgesia on the Accuracy of HVPG Measurements in Patients With Portal Hypertension
- Impact of Transjugular Intrahepatic Portosystemic Shunts on Liver Stiffness
- Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
- Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices
- Ivabradine in Cirrhotic Cardiomyopathy
- Laparoscopic Versus Open Devascularization for Portal Hypertension, a Randomized Controlled Trial
- Liver Incytes for Portal Hypertension
- Low Molecular Weight Heparin for the Prevention of Early TIPS Dysfunction
- MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy
- Microparticles in Cirrhosis and Portal Hypertension
- MRI in Portal Hypertension
- MRI to Assess the Effect of Non-selective Beta-blocker in Patients With Cirrhosis
- MRI to Assess the Effect of Terlipressin in Patients With Acute Hepatorenal Syndrome (HRS-AKI)
- Multimodal Ultrasound and Portal Hypertension
- Myocardial Fibrosis and Inflammation in Liver Cirrhosis
- Non Invasive Study of the Hepatic Fibrosis in Paediatrics by the Method of Study of Pediatric Hepatic Fibrosis
- Non-invasive Diagnosis of Portal Hypertension in Cirrhosis Based on Metabolomics Technology
- Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI)
- Non-invasive Evaluation Program for TIPS and Follow Up Network
- Non-invasive Evaluation Program for TIPS and Follow Up Network 2 (NEPTUN2)
- Non-invasive Method for Predicting the Presence of Gastroesophageal Varices in Patients With Cirrhosis
- Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension
- Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension
- Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
- Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
- Phase II Study of Lactulose and Circadian Rhythms in Patients With Cirrhosis
- Portal Hypertension and Systemic Endothelial Function
- Portal Hypertension Using Magnetic Resonance Elastography
- Portal Hypetension and Bariatric Surgery (BARIAPORTAL)
- Portal Pressure Effects of Phlebotomy Combined to Vasopressin Use in Cirrhotic Patients Undergoing Liver Transplantation
- Portal Vein Access During Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedures
- Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
- Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure
- Prevention of Esophageal Varices by Beta-Adrenergic Blockers
- Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
- Probiotics for Liver Cirrhosis With Portal Hypertension
- Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal Hypertension
- Quality of Life and Nutritional Improvements in Cirrhotic Patients
- Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension
- RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage
- Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis
- Relevance of Sarcopenia in Advanced Liver Disease
- Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients
- Risk Factors for Variceal Bleeding in Egyptian Patients With Non-Cirrhotic Portal Hypertension
- Role of SWE-change After TIPS in the Prediction of Prognosis After TIPS
- Secondary Prophylaxis After Variceal Bleeding in Non-Responders
- Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE
- Short Course Terlipressin for Control of Acute Variceal Bleeding
- Simvastatin Effect on Portal Hypertension
- Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
- Somatostatin in Living Donor Liver Transplantation
- Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis
- Splenic Embolization for Portal Hypertension
- Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis
- Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients
- Surrogate Markers of Portal Pressure
- Telesonography Adaptation and Use to Improve the Standard of Patient Care Within a Dominican Community
- The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients
- The Effect of Monitoring PVP on Clinical Outcomes in Patients With PH
- The Effect of Probiotics (VSL) on Portal Hypertension
- The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS
- The Influence of Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy
- The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study
- The International Imaging Registry in Liver Cirrhosis (BAVENO-VI SPSS GROUP).
- The Precise Selection of Stent Diameter for Portal Hypertension Patients With TIPS
- The Role of Somatostatin in the Hemodynamics of the Hepatic Circulation in Patients Undergoing Liver Resection
- The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
- The Timing of Emergency Endoscopy for Esophagogastric Variceal Bleeding in Cirrhosis
- The Use of Endoscopic Ultrasound-Guided Portal Pressure Measurements to Guide Beta-Blocker Therapy in Patients With Compensated Cirrhosis
- The Use of Propranolol for the Prevention of Worsening of Esophageal Varices in Patients With Isolated Gastric Varices
- The vPPG-detecting Software Guided Management of Cirrhotic Portal Hypertension
- Timing of Endoscopy for Acute Variceal Bleeding in Patients With Cirrhosis
- TIPS Combined With Microwave Ablation in HCC Patients With Refractory Ascites
- TIPS in Fundal Variceal Bleeding (the TFB Study)
- TIPS With 8- OR 10-mm Covered Stent for Preventing Variceal Rebleeding
- Transfusion Requirements in Gastrointestinal (GI) Bleeding
- Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C)
- Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response
- Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir
- Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir
- Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding
- Value of Von Willebrand Factor in Portal Hypertension
- Vasoactive Peptides in Portal Pressure
- Viatorr CX Case-control Study for Complications of Portal Hypertension
- VICIS – Vienna Cirrhosis Study
- Vonoprazan Efficacy to Prevent Post Variceal Band Ligation Ulcer
- WFA+M2BP in Evaluation of Portal Hypertension and Clinical Outcome in Patients With Liver Cirrhosis
- A Practical Nomogram Based on Systemic Inflammatory Markers for Predicting Portal Vein Thrombosis in Patients With Liver Cirrhosis
- Analysis of Neutrophil Extracellular Traps in Hypercoagulability and Portal Vein Thrombosis in Liver Cirrhosis Patients
- Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis
- Anticoagulation Post Laparoscopic Splenectomy
- Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
- Chances in Portal System Flow After Two Bariatric Procedures
- Clinical Course of Cirrhotic Patients With Portal Vein Thrombosis Treated With TIPS
- EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications
- Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver
- Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis
- Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis
- Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV
- Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis
- Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding
- Freiburg TIPS Registry
- Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome
- HAIC Combine With Lenvatinib and Camrelizumab for Advanced HCC With PVTT
- IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
- Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.
- Living Donor Liver Transplantation to Patients With Portal Vein Thrombosis
- Neo-TACE-HAIC for PVTT-HCC
- PADUA PREDICTION SCORE in Cirrhotic Patients
- Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis
- Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis
- Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis
- Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery
- Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
- Risk Factors for Recurrence of Thrombosis or Thrombotic Extension, in the Event of Acute Non-cirrhotic Portal Vein Thrombosis Secondary to a Local Cause.
- Role of EUS Guided FNA of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma
- Safety of Anticoagulant Therapy After Variceal Band Ligation
- SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
- Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis
- The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis
- The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT
- The Effect of Rifaximin on Portal Vein Thrombosis
- TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis
- TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV
- TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis
- Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis
- Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study
- Vienna Vascular Liver Disease Study
- Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
- Activity and Fatigue of the Respiratory Muscles and Pulmonary Characteristics in Post-Polio Patients
- Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis
- Enhance Wellness for Individuals With Long-Term Physical Disabilities
- Glutathione and Health With Post-Polio Syndrome
- Intravenous Immunoglobulins for Post-Polio Syndrome
- L-Citrulline in Patients With Post-Polio Syndrome
- Nomad P-KAFO Study
- Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)
- Spinal Cord Gray Matter Imaging in Post Polio Syndrome
- Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-polio Syndrome
- Whole Body Vibration on Muscle Strength in Patients With Postpolio Syndrome
- A Study of the Safety and Efficacy of EBV Specific T-cell Lines
- Bortezomib Plus Rituximab for EBV+ PTLD
- Cellular Immunotherapy for Viral Induced Cancer – EBV Positive Lymphomas
- Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
- Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
- Early Detection of Epstein-Barr Virus Related Disease.
- Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
- Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)
- High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
- Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
- Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
- Risk Stratified Sequential Treatment for CD20-positive PTLD
- Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy
- Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
- Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
- Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)
- Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
- Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
- Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder